弥漫大 B 细胞淋巴瘤患者 Th22 细胞及其细胞因子的表达及临床意义.

Objective: To investigate the expression and clinical significance of helper T (Th) 22 cell and its cytokines in patients with diffuse large B-cell lymphoma (DLBCL) . Methods: 121 patients with DLBCL (DLBCL group) and 70 healthy volunteers (control group) who were admitted to the First Affiliated Hospital of Hebei North University from June 2019 to June 2021 were selected. The percentage of Th22 cell and the levels of cytokines-interleukin (IL-22), IL-13, IL-6 and tumor necrosis factor (TNF) -α in peripheral blood before and after treatment were detected. The difference of levels of the percentage of Th22 and serum IL-22, IL-13, IL-6 and TNF-αwere compared between DLBCL group and control group, different AnnArbor clinical stages, International Prognosis Index (IPI) score and Hans immune classification and different efficacy of patients with DLBCL. Results: The percentage of Th22 cell in peripheral blood and the levels of serum of IL-22, IL-13, IL-6 and TNF-α in the DLBCL group were higher than those in the control group (P＜0.05) . The percentage of Th22 cell in peripheral blood, the levels of serum IL-22, IL-13, IL-6 and TNF-α in the stage Ⅲ～Ⅳ group, high-medium risk group and high risk group, and non-GCB group before treatment were higher than those in the stage I～ Ⅱ group, low risk group and low-medium risk group and GCB group, respectively (all P＜0.05) . 39 of 121 patients were judged to be non-responders to treatment,and the patients were divided into the ineffective group (n=39) and effective group (n=82) based on efficacy. The percentage of Th22 cell in peripheral blood and the levels of serum IL-22, IL-13, IL-6 and TNF-α in the ineffective group after treatment had no significant changes compared with those before treatment (P＞0.05), and the ineffective group before and after treatment were higher than the effective group (P＜0.05) . Conclusion: The percentage of Th22 in peripheral blood and the levels of serum IL-22, IL-13, IL-6 and TNF-α in patients with DLBCL increased, which are associated with high AnnArbor clinical stages, high IPI score, non-GCB type and poor clinical treatment effect. The clinic can adjust the treatment regimen by monitoring the levels of the above indicators and improve the effective rate of treatment. [ABSTRACT FROM AUTHOR]